Idexx Laboratories (IDXX) Receivables - Other (2018 - 2026)

Idexx Laboratories has reported Receivables - Other for 9 years, with the latest figure at $82.3 million in Q2 2026.

• On a quarterly basis, Receivables - Other rose 21.16% year-over-year to $82.3 million in Q2 2026; TTM through Jun 2026 was $82.3 million, a 21.16% increase from a year earlier, with the FY2025 full-year figure at $75.8 million, up 24.82% from the prior year.
• Receivables - Other was $82.3 million for Q2 2026 at Idexx Laboratories, up from $77.7 million in the prior quarter.
• The five-year high for Receivables - Other was $82.3 million in Q2 2026, with the low at $40.4 million in Q2 2022.
• Average Receivables - Other over 5 years is $58.1 million, with a median of $57.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Receivables - Other soared 56.51% in 2022, then climbed 10.23% in 2024.
• Over 5 years, Receivables - Other stood at $41.9 million in 2022, then surged by 31.67% to $55.1 million in 2023, then rose by 10.23% to $60.8 million in 2024, then increased by 24.82% to $75.8 million in 2025, then climbed by 8.51% to $82.3 million in 2026.
• The last three Receivables - Other figures came in at $82.3 million (Q2 2026), $77.7 million (Q1 2026), and $75.8 million (Q4 2025), per Business Quant data.